TickerSpark Feed

AMGN coverage

Every article, report, and earnings note where AMGN appears.

Amgen (AMGN): Growth Drivers Offset Leverage Risk

Amgen is executing well as six growth drivers offset patent losses, but heavy leverage and a rich valuation keep the stock in Hold territory.

Sep 17, 2026·18 MIN

Healthcare Drug Manufacturers - General Biotech

Trending StockAMGN

Amgen Inc. (AMGN) drops 8% after BMO downgrade

Amgen Inc. (AMGN) drops sharply after BMO Capital cut its rating from Outperform to Market Perform. The move comes despite solid earnings momentum, with investors weighing valuation, biosimilar pressure, and growth from Repatha and Tezspire.

Sep 8, 2026·5 MIN

IPOARIA

ARIAD Pharmaceuticals IPO Preview: Historical Biotech, Current Filing Gap

ARIAD Pharmaceuticals, Inc. (NYSE: ARIA) is expected to list on 2026-08-10, but the price range has not been disclosed. The key question is not valuation yet—it is whether this is a real upcoming IPO filing or a historical company reference that still needs confirmation. Bull case: a recognizable biotech name; bear case: the current offering details are not yet verified.

Aug 7, 2026·5 MIN

IPO NYSE

Trending StockAMGN

Amgen Inc. (AMGN) rises 6% after Q2 beat and outlook hike

Amgen Inc. (AMGN) rises after reporting a Q2 earnings beat and raising its full-year outlook. Strong sales growth in key products, improved cash flow, and fresh analyst target hikes helped push the stock above its 52-week high.

Aug 5, 2026·5 MIN

Top Stocks

Top Big Pharma Stocks: Our 5 Best Stock Picks for July 2026

Five big pharma stocks are ranked in a countdown, comparing specialty franchises, profitability, valuation, growth and earnings consistency for July 2026.

Jul 31, 2026·11 MIN

big pharma

SPAC

Talawar Tx SPAC Merger: Biotech Cash Runway Meets Dilution

Talawar Tx is a development-stage biotechnology company going public through a merger with JATT II Acquisition Corp. (ticker: JATT), with the combined company expected to trade as TLWR. The setup is attractive if you want exposure to a bispecific-antibody story with a large PIPE, but shareholders should watch redemption risk, dilution, and whether the cash really survives to the 2028 proof-of-concept readout.

Jul 5, 2026·6 MIN

SPAC Merger De-SPAC

IPOKARD

Kardigan, IPO: What to Know Before It Lists

Kardigan is expected to list on NASDAQ on 2026-06-18, with shares priced at $14.00 to $16.00. The IPO centers on a clinical-stage cardiovascular pipeline and a balance sheet that still needs capital to keep advancing. Watch whether investors focus on the three lead programs or the company’s going-concern warning.

Jun 15, 2026·5 MIN

IPO NASDAQ

Opinion

The GLP-1 trade is becoming a market-share war, not a rising-tide story

Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.

Jun 3, 2026·5 MIN

GLP-1 Healthcare Competition

Top Stocks

Dividend Growth Stocks to Own in September 2026: 7 Names

A seven-stock countdown spans beverages, restaurants, biopharmaceuticals and consumer staples, showing how dividend growth can blend income, defensiveness and earnings durability.

Jun 3, 2026·14 MIN

dividend growth

Top Stocks

Best Biotech Stocks for September 2026: 7 Research Candidates

A seven-stock biotech countdown spans rare-disease developers, CNS specialists, platform collaborations and commercial-stage therapeutic franchises.

May 27, 2026·13 MIN

biotech

Trending StockAMGN

Amgen Inc. (AMGN) drops 5.9% after Q1 earnings beat

Amgen Inc. (AMGN) drops after reporting first-quarter 2026 results, even though the company beat Wall Street on earnings and revenue. Investors appear focused on valuation, growth quality, and whether the quarter was strong enough to justify the stock’s premium.